The Market for the Making of IVD Products is 15 Billion: Report

The global in vitro diagnostic (IVD) industry incorporates a sizable contract manufacturing segment that supplies a full range of reagents and test kits, instruments and systems, and testing accessories. This according to Kalorama Information’s latest report on Contract Manufacturing in IVD: https://kaloramainformation.com/product/the-market-for-contract-manufacturing-in-in-vitro-diagnostics-ivd/. The market will grow at double the rate of the overall IVD market, […]

This Week in Cell and Gene Therapy: 11 New Developments to Know (September 12, 2022)

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Kite Pharma, a Gilead Company based in Santa Monica, CA, has announced that the European Commission (EC) has granted approval for its chimeric antigen receptor (CAR) T cell therapy Tecartus […]

BCMOs: Who’s Winning?

The global BCMO industry is highly fragmented, with 40 BCMOs/CDMOs accounting for roughly one quarter of the industry’s revenues and the remainder comprised of a large number of smaller players. Based upon 2021 figures, Catalent led the overall market with estimated BCMO sales of $2.2 billion It was followed closely by Cytiva with $2.0 billion […]

CMOs Thrive on New Trend: Pharma Personnel Shortages

Biotechnology BCMO services, including both clinical and commercial production, were estimated at $11.9 billion in 2021. This according to the just-published Kalorama market analysis of the BCMO market. – https://kaloramainformation.com/product/biopharmaceutical-contract-manufacturing-organization-cmo-market-2022/ This segment has been expanding strongly by an estimated 13% per year since 2016, with increased growth of 15.5% per year from 2021 to 2026. […]

What Will Be the Next Emerging Disease Requiring IVDs?

Kalorama estimates a $3.7 billion market for emerging diseases. This market is expected to grow to $4.9 billion in 2026. This is based on it’s latest report: Emerging Infectious Disease Market, released August 2022: https://kaloramainformation.com/product/emerging-infectious-disease-diagnostics-markets-and-trends-2022/ In 2015 the World Health Organization held a workshop on prioritization of pathogens “for accelerated R&D for severe emerging diseases […]

127.4 Billion-Dollar IVD Market Blooms

Abbott Leads, Roche Close Second. COVID -19 Tests Largest Share, But Growth Comes from non-COVID The world in vitro diagnostic (IVD) market will reach $127.4 billion dollars in 2022, according to LabPulse.com’s sister publication Kalorama Information.  That’s the finding from the firm’s market research report, The Worldwide Market for In Vitro Diagnostics, 15th edition.  REPORT: […]

This Week in Cell and Gene Therapy: 8 New Developments to Know (August 22, 2022)

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Prescient Therapeutics, a clinical stage oncology company based in Melbourne, Australia, has signed a five-year manufacturing agreement with Q-Gen Cell Therapeutics, a specialist cell therapy manufacturer based at the QIMR […]

American College of Physicians Discourages DTC Genetic Testing

A recent article in the ACP journal discourages the use of DTC genetic testing and recommends that testing be undertaken in the context of a patient-physician relationship with appropriate counseling. Physicians, healthcare systems, and others with access to patient data must safeguard the privacy, confidentiality, and security of patient information, including genomic information, ACP noted. […]

This Week in Cell and Gene Therapy: 10 New Developments to Know (August 9, 2022)

What You May Have Missed at AACC 2022: Free White Paper

From a biosensor that won AACC’s disruptive technology award, to a new use for AI in IVD, to the realities of automation at real-world laboratories, this year’s AACC conference had a lot to offer. Many Kalorama customers either were not able to make the show or were at the show but may have missed a […]